Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584834 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL7722108 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL1967676 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL18313954 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL1975610 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL15151157 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL1975652 | 0.91 | CHRM2 (0.47) | CHRM2CHRM1CHRM3CYP3A4HSD17B10 | |
| SCHEMBL60188 | 0.88 | NR1H2 (0.42) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL14210999 | 0.88 | NR1H2 (0.42) | CHRM2CHRM1CHRM3ALDH1A1CYP3A4 | |
| SCHEMBL18555624 | 0.88 | NR1H2 (0.42) | CHRM2CHRM1CHRM3CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577258-B2 | Macrocyclic compound | VERNALIS (R&D) LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20250250287-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE SWITZERLAND GMBH (CH) | 2025-08-07 | — | — | US | disclosed |
| US-20250205167-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES, INC. | 2025-06-26 | — | — | US | disclosed |
| EP-4568973-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene Switzerland GmbH (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-4223368-B1 | MACROCYCLIC COMPOUNDS INCORPORATING PIPERIDINE AND QUINOLINE OR QUNAXOLINE AS IRAK-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | ASAHI KASEI PHARMA CORP (JP) | 2025-05-21 | — | — | EP | disclosed |
| CN-119654327-A | Heterocyclic compounds, compositions thereof and methods of treatment thereof | 百济神州(苏州)生物科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4499607-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | Sail Biomedicines, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119072464-A | Novel ionizable lipids and lipid nanoparticles and methods of use thereof | 赛欧生物医药股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| WO-2024041573-A1 | FUSED MULTI-HETEROCYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024032703-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2024-02-15 | — | — | WO | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
| EP-1844062-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | Methylgene, Inc. (CA) | 2007-10-17 | — | — | EP | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006078752-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | METHYLGENE, INC. (CA) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| EP-0805681-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0805681-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022775-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205167-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | PHOSPHO1, SGMS2, SGMS1 | CHRM2 4417/4885CHRM1 4686/4885CHRM3 4044/4885 |
| US-12577258-B2 | Macrocyclic compound | IRAK1, IRAK4, IRAK2 | CHRM2 2345/4885CHRM1 1255/4885CHRM3 1610/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | CHRM2 2683/4885CHRM1 2992/4885CHRM3 2727/4885 |
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | CHRM2 33/4885CHRM1 40/4885CHRM3 17/4885 |
| US-20250250287-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | KRAS, NRAS, HRAS | CHRM2 4777/4885CHRM1 4809/4885CHRM3 4722/4885 |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | DNMT3B, DNMT1, DNMT3L | CHRM2 3234/4885CHRM1 3222/4885CHRM3 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.